Treatment of severe or progressive Kaposi's sarcoma in HIV-infected adults
Identifieur interne : 001660 ( Pmc/Checkpoint ); précédent : 001659; suivant : 001661Treatment of severe or progressive Kaposi's sarcoma in HIV-infected adults
Auteurs : Oluwatoyin F. Gbabe [Afrique du Sud] ; Charles I. Okwundu [Afrique du Sud] ; Martin Dedicoat [Royaume-Uni] ; Esther E. Freeman [États-Unis]Source :
- The Cochrane database of systematic reviews [ 1469-493X ] ; 2014.
Abstract
Kaposi's sarcoma remains the most common cancer in Sub-Saharan Africa and the second most common cancer in HIV-infected patients worldwide. Since the introduction of highly active antiretroviral therapy (HAART), there has been a decline in its incidence. However, Kaposi's sarcoma continues to be diagnosed in HIV-infected patients.
To assess the added advantage of chemotherapy plusHAART compared toHAART alone; and the advantages of different chemotherapy regimens in HAART and HAART naive HIV infected adults with severe or progressive Kaposi's sarcoma.
We searched the Cochrane Central Register of Controlled Trials (CENTRAL), MEDLINE, EMBASE and GATEWAY, the WHO Clinical Trials Registry Platform and the US National Institutes of Health's Clinical Trials.gov for ongoing trials and the Aegis archive of HIV/AIDS for conference abstracts. An updated search was conducted in July 2014.
Randomised trials and observational studies evaluating the effects of any chemotherapeutic regimen in combination with HAART compared to HAART alone, chemotherapy versus HAART, and comparisons between different chemotherapy regimens.
Two review authors assessed the studies independently and extracted outcome data. We used the risk ratio (RR) with a 95% confidence interval (CI) as the measure of effect. We did not conduct meta-analysis as none of the included trials assessed identical chemotherapy regimens.
Url:
PubMed: 25221796
PubMed Central: 4174344
Affiliations:
Links toward previous steps (curation, corpus...)
Links to Exploration step
PMC:4174344Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Treatment of severe or progressive Kaposi's sarcoma in HIV-infected adults</title>
<author><name sortKey="Gbabe, Oluwatoyin F" sort="Gbabe, Oluwatoyin F" uniqKey="Gbabe O" first="Oluwatoyin F" last="Gbabe">Oluwatoyin F. Gbabe</name>
<affiliation wicri:level="1"><nlm:aff id="A1">Community Health Division, Faculty of Medicine and Health Sciences, Stellenbosch University, Cape Town, South Africa</nlm:aff>
<country xml:lang="fr">Afrique du Sud</country>
<wicri:regionArea>Community Health Division, Faculty of Medicine and Health Sciences, Stellenbosch University, Cape Town</wicri:regionArea>
<wicri:noRegion>Cape Town</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Okwundu, Charles I" sort="Okwundu, Charles I" uniqKey="Okwundu C" first="Charles I" last="Okwundu">Charles I. Okwundu</name>
<affiliation wicri:level="1"><nlm:aff id="A2">Centre for Evidence-based Health Care, Faculty of Medicine and Health Sciences, Stellenbosch University, Cape Town, South Africa</nlm:aff>
<country xml:lang="fr">Afrique du Sud</country>
<wicri:regionArea>Centre for Evidence-based Health Care, Faculty of Medicine and Health Sciences, Stellenbosch University, Cape Town</wicri:regionArea>
<wicri:noRegion>Cape Town</wicri:noRegion>
</affiliation>
<affiliation wicri:level="1"><nlm:aff id="A3">South African Cochrane Centre, South African Medical Research Council, Tygerberg, South Africa</nlm:aff>
<country xml:lang="fr">Afrique du Sud</country>
<wicri:regionArea>South African Cochrane Centre, South African Medical Research Council, Tygerberg</wicri:regionArea>
<wicri:noRegion>Tygerberg</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Dedicoat, Martin" sort="Dedicoat, Martin" uniqKey="Dedicoat M" first="Martin" last="Dedicoat">Martin Dedicoat</name>
<affiliation wicri:level="3"><nlm:aff id="A4">Department of Infection, Birmingham Heartlands Hospital, Birmingham, UK</nlm:aff>
<country xml:lang="fr">Royaume-Uni</country>
<wicri:regionArea>Department of Infection, Birmingham Heartlands Hospital, Birmingham</wicri:regionArea>
<placeName><settlement type="city">Birmingham</settlement>
<region type="country">Angleterre</region>
<region type="région" nuts="1">Midlands de l'Ouest</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Freeman, Esther E" sort="Freeman, Esther E" uniqKey="Freeman E" first="Esther E" last="Freeman">Esther E. Freeman</name>
<affiliation wicri:level="2"><nlm:aff id="A5">Department of Dermatology, Massachusetts General Hospital, Boston, Massachusetts, USA</nlm:aff>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Department of Dermatology, Massachusetts General Hospital, Boston, Massachusetts</wicri:regionArea>
<placeName><region type="state">Massachusetts</region>
</placeName>
</affiliation>
<affiliation wicri:level="2"><nlm:aff id="A6">Department of Dermatology, Harvard Medical School, Boston, Massachusetts, USA</nlm:aff>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Department of Dermatology, Harvard Medical School, Boston, Massachusetts</wicri:regionArea>
<placeName><region type="state">Massachusetts</region>
</placeName>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">PMC</idno>
<idno type="pmid">25221796</idno>
<idno type="pmc">4174344</idno>
<idno type="url">http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4174344</idno>
<idno type="RBID">PMC:4174344</idno>
<date when="2014">2014</date>
<idno type="wicri:Area/Pmc/Corpus">003438</idno>
<idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Corpus" wicri:corpus="PMC">003438</idno>
<idno type="wicri:Area/Pmc/Curation">003437</idno>
<idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Curation">003437</idno>
<idno type="wicri:Area/Pmc/Checkpoint">001660</idno>
<idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Checkpoint">001660</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en" level="a" type="main">Treatment of severe or progressive Kaposi's sarcoma in HIV-infected adults</title>
<author><name sortKey="Gbabe, Oluwatoyin F" sort="Gbabe, Oluwatoyin F" uniqKey="Gbabe O" first="Oluwatoyin F" last="Gbabe">Oluwatoyin F. Gbabe</name>
<affiliation wicri:level="1"><nlm:aff id="A1">Community Health Division, Faculty of Medicine and Health Sciences, Stellenbosch University, Cape Town, South Africa</nlm:aff>
<country xml:lang="fr">Afrique du Sud</country>
<wicri:regionArea>Community Health Division, Faculty of Medicine and Health Sciences, Stellenbosch University, Cape Town</wicri:regionArea>
<wicri:noRegion>Cape Town</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Okwundu, Charles I" sort="Okwundu, Charles I" uniqKey="Okwundu C" first="Charles I" last="Okwundu">Charles I. Okwundu</name>
<affiliation wicri:level="1"><nlm:aff id="A2">Centre for Evidence-based Health Care, Faculty of Medicine and Health Sciences, Stellenbosch University, Cape Town, South Africa</nlm:aff>
<country xml:lang="fr">Afrique du Sud</country>
<wicri:regionArea>Centre for Evidence-based Health Care, Faculty of Medicine and Health Sciences, Stellenbosch University, Cape Town</wicri:regionArea>
<wicri:noRegion>Cape Town</wicri:noRegion>
</affiliation>
<affiliation wicri:level="1"><nlm:aff id="A3">South African Cochrane Centre, South African Medical Research Council, Tygerberg, South Africa</nlm:aff>
<country xml:lang="fr">Afrique du Sud</country>
<wicri:regionArea>South African Cochrane Centre, South African Medical Research Council, Tygerberg</wicri:regionArea>
<wicri:noRegion>Tygerberg</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Dedicoat, Martin" sort="Dedicoat, Martin" uniqKey="Dedicoat M" first="Martin" last="Dedicoat">Martin Dedicoat</name>
<affiliation wicri:level="3"><nlm:aff id="A4">Department of Infection, Birmingham Heartlands Hospital, Birmingham, UK</nlm:aff>
<country xml:lang="fr">Royaume-Uni</country>
<wicri:regionArea>Department of Infection, Birmingham Heartlands Hospital, Birmingham</wicri:regionArea>
<placeName><settlement type="city">Birmingham</settlement>
<region type="country">Angleterre</region>
<region type="région" nuts="1">Midlands de l'Ouest</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Freeman, Esther E" sort="Freeman, Esther E" uniqKey="Freeman E" first="Esther E" last="Freeman">Esther E. Freeman</name>
<affiliation wicri:level="2"><nlm:aff id="A5">Department of Dermatology, Massachusetts General Hospital, Boston, Massachusetts, USA</nlm:aff>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Department of Dermatology, Massachusetts General Hospital, Boston, Massachusetts</wicri:regionArea>
<placeName><region type="state">Massachusetts</region>
</placeName>
</affiliation>
<affiliation wicri:level="2"><nlm:aff id="A6">Department of Dermatology, Harvard Medical School, Boston, Massachusetts, USA</nlm:aff>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Department of Dermatology, Harvard Medical School, Boston, Massachusetts</wicri:regionArea>
<placeName><region type="state">Massachusetts</region>
</placeName>
</affiliation>
</author>
</analytic>
<series><title level="j">The Cochrane database of systematic reviews</title>
<idno type="eISSN">1469-493X</idno>
<imprint><date when="2014">2014</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><textClass></textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en"><sec id="S1"><title>Background</title>
<p id="P1">Kaposi's sarcoma remains the most common cancer in Sub-Saharan Africa and the second most common cancer in HIV-infected patients worldwide. Since the introduction of highly active antiretroviral therapy (HAART), there has been a decline in its incidence. However, Kaposi's sarcoma continues to be diagnosed in HIV-infected patients.</p>
</sec>
<sec id="S2"><title>Objectives</title>
<p id="P2">To assess the added advantage of chemotherapy plusHAART compared toHAART alone; and the advantages of different chemotherapy regimens in HAART and HAART naive HIV infected adults with severe or progressive Kaposi's sarcoma.</p>
</sec>
<sec id="S3"><title>Search methods</title>
<p id="P3">We searched the Cochrane Central Register of Controlled Trials (CENTRAL), MEDLINE, EMBASE and GATEWAY, the WHO Clinical Trials Registry Platform and the US National Institutes of Health's Clinical Trials.gov for ongoing trials and the Aegis archive of HIV/AIDS for conference abstracts. An updated search was conducted in July 2014.</p>
</sec>
<sec id="S4"><title>Selection criteria</title>
<p id="P4">Randomised trials and observational studies evaluating the effects of any chemotherapeutic regimen in combination with HAART compared to HAART alone, chemotherapy versus HAART, and comparisons between different chemotherapy regimens.</p>
</sec>
<sec id="S5"><title>Data collection and analysis</title>
<p id="P5">Two review authors assessed the studies independently and extracted outcome data. We used the risk ratio (RR) with a 95% confidence interval (CI) as the measure of effect. We did not conduct meta-analysis as none of the included trials assessed identical chemotherapy regimens.</p>
</sec>
</div>
</front>
</TEI>
<pmc article-type="research-article"><pmc-comment>The publisher of this article does not allow downloading of the full text in XML form.</pmc-comment>
<pmc-dir>properties manuscript</pmc-dir>
<front><journal-meta><journal-id journal-id-type="nlm-journal-id">100909747</journal-id>
<journal-id journal-id-type="pubmed-jr-id">21711</journal-id>
<journal-id journal-id-type="nlm-ta">Cochrane Database Syst Rev</journal-id>
<journal-id journal-id-type="iso-abbrev">Cochrane Database Syst Rev</journal-id>
<journal-title-group><journal-title>The Cochrane database of systematic reviews</journal-title>
</journal-title-group>
<issn pub-type="epub">1469-493X</issn>
</journal-meta>
<article-meta><article-id pub-id-type="pmid">25221796</article-id>
<article-id pub-id-type="pmc">4174344</article-id>
<article-id pub-id-type="manuscript">NIHMS625932</article-id>
<article-categories><subj-group subj-group-type="heading"><subject>Article</subject>
</subj-group>
</article-categories>
<title-group><article-title>Treatment of severe or progressive Kaposi's sarcoma in HIV-infected adults</article-title>
</title-group>
<contrib-group><contrib contrib-type="author"><name><surname>Gbabe</surname>
<given-names>Oluwatoyin F</given-names>
</name>
<xref ref-type="aff" rid="A1">1</xref>
</contrib>
<contrib contrib-type="author"><name><surname>Okwundu</surname>
<given-names>Charles I</given-names>
</name>
<xref ref-type="aff" rid="A2">2</xref>
<xref ref-type="aff" rid="A3">3</xref>
</contrib>
<contrib contrib-type="author"><name><surname>Dedicoat</surname>
<given-names>Martin</given-names>
</name>
<xref ref-type="aff" rid="A4">4</xref>
</contrib>
<contrib contrib-type="author"><name><surname>Freeman</surname>
<given-names>Esther E</given-names>
</name>
<xref ref-type="aff" rid="A5">5</xref>
<xref ref-type="aff" rid="A6">6</xref>
</contrib>
</contrib-group>
<aff id="A1"><label>1</label>
Community Health Division, Faculty of Medicine and Health Sciences, Stellenbosch University, Cape Town, South Africa</aff>
<aff id="A2"><label>2</label>
Centre for Evidence-based Health Care, Faculty of Medicine and Health Sciences, Stellenbosch University, Cape Town, South Africa</aff>
<aff id="A3"><label>3</label>
South African Cochrane Centre, South African Medical Research Council, Tygerberg, South Africa</aff>
<aff id="A4"><label>4</label>
Department of Infection, Birmingham Heartlands Hospital, Birmingham, UK</aff>
<aff id="A5"><label>5</label>
Department of Dermatology, Massachusetts General Hospital, Boston, Massachusetts, USA</aff>
<aff id="A6"><label>6</label>
Department of Dermatology, Harvard Medical School, Boston, Massachusetts, USA</aff>
<author-notes><corresp id="FN1">Contact address: Oluwatoyin F Gbabe, Community Health Division, Faculty of Medicine and Health Sciences, Stellenbosch University, Francie van Zijl Drive, Tygerberg, Cape Town, 7505, South Africa. <email>gbabetoyin@yahoo.com</email>
</corresp>
</author-notes>
<pub-date pub-type="nihms-submitted"><day>7</day>
<month>9</month>
<year>2014</year>
</pub-date>
<pub-date pub-type="epub"><day>13</day>
<month>8</month>
<year>2014</year>
</pub-date>
<pub-date pub-type="collection"><year>2014</year>
</pub-date>
<pub-date pub-type="pmc-release"><day>13</day>
<month>8</month>
<year>2015</year>
</pub-date>
<volume>8</volume>
<fpage>CD003256</fpage>
<lpage>CD003256</lpage>
<permissions><copyright-statement>Copyright © 2014 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.</copyright-statement>
<copyright-year>2014</copyright-year>
</permissions>
<abstract><sec id="S1"><title>Background</title>
<p id="P1">Kaposi's sarcoma remains the most common cancer in Sub-Saharan Africa and the second most common cancer in HIV-infected patients worldwide. Since the introduction of highly active antiretroviral therapy (HAART), there has been a decline in its incidence. However, Kaposi's sarcoma continues to be diagnosed in HIV-infected patients.</p>
</sec>
<sec id="S2"><title>Objectives</title>
<p id="P2">To assess the added advantage of chemotherapy plusHAART compared toHAART alone; and the advantages of different chemotherapy regimens in HAART and HAART naive HIV infected adults with severe or progressive Kaposi's sarcoma.</p>
</sec>
<sec id="S3"><title>Search methods</title>
<p id="P3">We searched the Cochrane Central Register of Controlled Trials (CENTRAL), MEDLINE, EMBASE and GATEWAY, the WHO Clinical Trials Registry Platform and the US National Institutes of Health's Clinical Trials.gov for ongoing trials and the Aegis archive of HIV/AIDS for conference abstracts. An updated search was conducted in July 2014.</p>
</sec>
<sec id="S4"><title>Selection criteria</title>
<p id="P4">Randomised trials and observational studies evaluating the effects of any chemotherapeutic regimen in combination with HAART compared to HAART alone, chemotherapy versus HAART, and comparisons between different chemotherapy regimens.</p>
</sec>
<sec id="S5"><title>Data collection and analysis</title>
<p id="P5">Two review authors assessed the studies independently and extracted outcome data. We used the risk ratio (RR) with a 95% confidence interval (CI) as the measure of effect. We did not conduct meta-analysis as none of the included trials assessed identical chemotherapy regimens.</p>
</sec>
</abstract>
<kwd-group><title>Medical Subject Headings (MeSH)</title>
<kwd>Antineoplastic Agents [therapeutic use]</kwd>
<kwd>Doxorubicin [therapeutic use]</kwd>
<kwd>HIV Infections [*complications]</kwd>
<kwd>Liposomes; Randomized Controlled Trials as Topic</kwd>
<kwd>Sarcoma, Kaposi [*therapy</kwd>
<kwd>virology]</kwd>
<kwd>Skin Neoplasms [*therapy]</kwd>
<kwd>Tretinoin [therapeutic use]</kwd>
</kwd-group>
<kwd-group><title>MeSH check words</title>
<kwd>Humans</kwd>
</kwd-group>
</article-meta>
</front>
</pmc>
<affiliations><list><country><li>Afrique du Sud</li>
<li>Royaume-Uni</li>
<li>États-Unis</li>
</country>
<region><li>Angleterre</li>
<li>Massachusetts</li>
<li>Midlands de l'Ouest</li>
</region>
<settlement><li>Birmingham</li>
</settlement>
</list>
<tree><country name="Afrique du Sud"><noRegion><name sortKey="Gbabe, Oluwatoyin F" sort="Gbabe, Oluwatoyin F" uniqKey="Gbabe O" first="Oluwatoyin F" last="Gbabe">Oluwatoyin F. Gbabe</name>
</noRegion>
<name sortKey="Okwundu, Charles I" sort="Okwundu, Charles I" uniqKey="Okwundu C" first="Charles I" last="Okwundu">Charles I. Okwundu</name>
<name sortKey="Okwundu, Charles I" sort="Okwundu, Charles I" uniqKey="Okwundu C" first="Charles I" last="Okwundu">Charles I. Okwundu</name>
</country>
<country name="Royaume-Uni"><region name="Angleterre"><name sortKey="Dedicoat, Martin" sort="Dedicoat, Martin" uniqKey="Dedicoat M" first="Martin" last="Dedicoat">Martin Dedicoat</name>
</region>
</country>
<country name="États-Unis"><region name="Massachusetts"><name sortKey="Freeman, Esther E" sort="Freeman, Esther E" uniqKey="Freeman E" first="Esther E" last="Freeman">Esther E. Freeman</name>
</region>
<name sortKey="Freeman, Esther E" sort="Freeman, Esther E" uniqKey="Freeman E" first="Esther E" last="Freeman">Esther E. Freeman</name>
</country>
</tree>
</affiliations>
</record>
Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/LymphedemaV1/Data/Pmc/Checkpoint
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001660 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Pmc/Checkpoint/biblio.hfd -nk 001660 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien |wiki= Wicri/Sante |area= LymphedemaV1 |flux= Pmc |étape= Checkpoint |type= RBID |clé= PMC:4174344 |texte= Treatment of severe or progressive Kaposi's sarcoma in HIV-infected adults }}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Pmc/Checkpoint/RBID.i -Sk "pubmed:25221796" \ | HfdSelect -Kh $EXPLOR_AREA/Data/Pmc/Checkpoint/biblio.hfd \ | NlmPubMed2Wicri -a LymphedemaV1
This area was generated with Dilib version V0.6.31. |